

UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY

HORIZON PHARMA IRELAND
LIMITED, et al.,

Civil No. 14-7992 (NLH/AMD)

Plaintiffs,

ORDER

v.

ACTAVIS LABORATORIES, UT,
INC., et al.,

Defendants.

For the reasons expressed in the Court's Opinion filed
today,

IT IS on this 17th day of August, 2016

ORDERED that the Court's construction of the disputed claim
terms in U.S. Patent Nos. 8,252,838 ("the '838 patent"),
8,563,613 ("the '613 patent"), 8,871,809 ("the '809 patent"),
9,066,913 ("the '913 patent"), 9,101,591 ("the '591 patent"),
8,546,450 ("the '450 patent"), 8,217,078 ("the '078 patent"),
8,618,164 ("the '164 patent") and 9,132,110 ("the '110 patent")
is as follows:

1. "the topical formulation produces less than 0.1% impurity A after 6 months at 25°C and 60% humidity" is indefinite as to the identity of "impurity A"
2. "the formulation degrades by less than 1% over 6 months" is indefinite
3. "consisting essentially of" is indefinite due to indefiniteness of the basic and novel properties of

the invention.

At Camden, New Jersey

s/ Noel L. Hillman
NOEL L. HILLMAN, U.S.D.J.